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Utilisation and outcomes of cervical cancer prevention 
services among HIV-infected women in Cape Town 
Priya Batra, Louise Kuhn, Lynette Denny
Cervical cancer is the most common cancer among South 
African women. The age-standardised mortality rate from 
cervical cancer is 21.0% in South Africa but only 8.9% 
worldwide.1,2 This differential highlights inequality in the 
availability of screening for easily treated precursor lesions. 
South Africa’s cervical cancer burden severity is compounded 
by its HIV epidemic (2008 adult prevalence rate 18.1%).3 
In HIV-infected women, the risk of developing squamous 
intraepithelial lesions (SIL) is increased, and the annual 
incidence of human papillomavirus (HPV)-associated cervical 
intraepithelial neoplasia (CIN) is 4 - 5 times greater than in 
the general population.4,5 CIN appears in younger women and 
progresses to cancer more quickly in the presence of HIV.6 
Cancer screening rates in South Africa are low, regardless of 
HIV status. Papanicolaou (Pap) screening rates are as low as 
4% among women 15 - 65 years of age, with most performed 
in antenatal or family planning clinics.7 In 2000, the South 
African Department of Health published guidelines for a 
comprehensive national cervical cancer screening programme. 
All asymptomatic women of at least 30 years of age should be 
offered three free lifetime Pap smears, up to 10 years apart.8 
This policy did not take HIV status into account, and there are 
few evidence-based guidelines for cervical cancer screening in 
HIV-positive women.
We aimed to evaluate the provision of cervical cancer 
prevention services to HIV-positive women in Cape Town. 
First, we attempted to define the proportion of HIV-positive 
women undergoing Pap smears at HIV primary health clinics 
(PHCs) in the community. Second, we audited the Groote 
Schuur Hospital (GSH) colposcopy clinic to describe the impact 
of HIV status on diagnosis and management of precursors to 
cervical cancer. 
Methods
Study design and subjects
We conducted a retrospective review of clinic registers, patient 
medical records and pathology databases at three HIV PHCs in 
Cape Town and the GSH colposcopy clinic, which is a tertiary 
referral site for a large proportion of women undergoing 
cervical screening in Cape Town.
PHCs serving HIV-positive women
The PHC sample included all women at three selected HIV 
clinics who were aged at least 16 years, had been tested for 
HIV between 1 August 2006 and 31 July 2008, and were 
receiving care for HIV. Western Cape Department of Health 
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Objective. An audit of outcomes of cervical cancer screening 
and prevention services for HIV-positive women in Cape 
Town, South Africa. 
Design. Retrospective review of clinic registers, patient records 
and pathology databases at three HIV primary health clinics 
and a tertiary colposcopy referral centre.
Subjects. Women recently diagnosed with HIV at three 
primary health clinics between 2006 and 2008 (N=2 240); 
new patients seen for colposcopy at a tertiary referral centre 
between 2006 and 2009 (N=2 031).
Outcome measures. The proportion of women undergoing 
cervical cancer screening after HIV diagnosis at primary 
health clinics, demographic characteristics of women referred 
for colposcopy at a tertiary centre, and outcomes of therapy 
for precancerous lesions of the cervix.
Results. The proportion of women undergoing at least one 
Pap smear at HIV primary health clinics after HIV diagnosis 
was low (13.1%). Women referred for colposcopy tended to 
be HIV-positive and over the age of 30 years, and in most 
(70.2%) cytological examination revealed high-grade cervical 
dysplasia. HIV-positive women treated with excision for 
precancerous lesions of the cervix were significantly more 
likely than their HIV-negative counterparts to undergo 
incomplete excision, experience persistent cervical disease 
after treatment, and be lost to follow-up.
Conclusion. Cervical cancer screening efforts must be scaled up 
for women with HIV. Treatment and surveillance guidelines 
for cervical intraepithelial neoplasia in HIV-positive women 
may need to be revised and new interventions developed to 
reduce incomplete treatment and patient default. 
S Afr Med J 2010; 100: 39-44.
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policy specifies that HIV-positive women should undergo 
annual cervical screening by Pap smear, the first performed 
just after HIV diagnosis. The three HIV PHC sites selected 
were known to refer patients with abnormal smears to GSH 
for colposcopy. Data captured included PHC location, age, 
whether the woman underwent a Pap smear, cytology results 
and any details regarding referral for colposcopy. For the 
subject to be included, Pap smears had to have been performed 
after HIV diagnosis and before 1 December 2008.
GSH colposcopy clinic
This sample included all women at least 16 years of age 
referred between 1 January 2006 and 31 December 2008 as 
new patients for colposcopy from family planning clinics, 
community health centres and workplace clinics in Cape 
Town. Indications for referral to colposcopy were an abnormal 
glandular lesion on Pap smear, a single result of high-grade SIL 
or cancer, or two or more low-grade SIL or atypical squamous 
results on Pap smears taken at least 6 months apart. Patient 
encounters occurring before 1 January 2009 were reviewed. 
The final sample included 2 045 women, of whom 2 031 
had records available for review (99.3% completion). Data 
were collected for the first colposcopy visit for all subjects. For 
subjects undergoing large loop excision of the transformation 
zone (LLETZ) for treatment of CIN, data were also collected for 
the treatment visit and for the 4-month post-procedure visit. 
Indicators captured from colposcopy charts and pathology 
databases included demographics (age, gravidity/parity, 
co-morbid genital warts/herpes, co-morbid pulmonary 
tuberculosis, contraceptive use), self-reported HIV status, self-
reported use of highly active antiretroviral therapy (HAART), 
smoking status, Pap smear results, colposcopy findings, 
histological diagnoses and compliance with follow-up visits. 
Laboratory results (cytology, histology) were recorded as 
reported by the National Health Laboratory Service (NHLS), 
which serves all PHC sites and GSH. 
Statistical analysis
Data were entered into an anonymous database using Access 
2000 software (Microsoft, Seattle, WA), and exported into SAS 
9.1.3 (SAS Institute, Cary, NC) for analysis. Proportions of 
subjects undergoing Pap tests were calculated for PHC sites. 
Descriptive statistics were generated for demographic data in 
the GSH sample. We used the chi-square (χ2) statistic to test for 
differences in outcomes by categorical variables, with statistical 
significance defined at alpha = 0.05 (p≤0.050). Outcome 
variables included whether a Pap smear was performed, 
colposcopy findings and cytology/histology pre- and post-
treatment. Hypothesised determinant variables included age, 
contraceptive method, self-reported HIV status and HAART 
use.
Ethics considerations
Ethics approval was obtained from the Research Ethics 
Committee of the University of Cape Town Health Sciences 
Faculty and from the Columbia University Institutional Review 
Board (New York, USA).
Results
Pap smears performed among HIV-positive women 
at PHCs
The final PHC sample included 2 240 HIV-positive women at 
three clinic sites (Table I); 52.4% were 30 years of age or older, 
Table I. Descriptive statistics for HIV primary health centre sample – clients recently testing HIV positive 
      Entire sample         Women <30 years     Women ≥30 years
      (N=2 240)          (N=1 066)      (N=1 174)
Characteristic     (N (%))          (N (%))       (N (%))
At least one Pap smear done    293 (13.1)          113 (10.6)      180 (15.3)
Result of first Pap smear 
(if available)
Normal     128 (56.6)          52 (55.9)      76 (57.1)
ASCUS      15 (6.6)          4 (4.3)      11 (8.3)
LSIL      63 (27.9)          28 (30.1)      35 (26.3)
HSIL      6 (2.7)          3 (3.2)      3 (2.3)
Cancer      1 (0.4)          0 (0.0)      1 (0.8)
Inadequate smear    13 (5.8)          6 (6.5)      7 (5.3)
Referred for colposcopy, given at least one Pap smear 12 (4.1)*          3 (2.7)      9 (5.0)
Indication for colposcopy
Recurrent LSIL     3 (25.0)          0 (0.0)      3 (33.3)
HSIL      6 (50.0)          3 (100.0)      3 (33.3)
Cancer      1 (8.3)          0 (0.0)      1 (11.1)
Other reason     2 (16.7)          0 (0.0)      2 (22.2)
*Colposcopy was indicated in 10 referred cases (appropriate referrals), and not indicated in 2 referred cases (inappropriate referrals); 2 additional cases were not appropriately referred for 
colposcopy (missed cases). 
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and only 293 (13.1%) had had at least one Pap smear between 
HIV diagnosis and the end of the data collection period. Older 
women were significantly more likely to have had at least one 
Pap smear (p=0.0021). The proportion of women having at 
least one Pap smear was stratified by clinic site (A, B or C). At 
site A, 688 women tested HIV positive, of whom 72 (10.5%) 
had a Pap smear, compared with 92 of 1 346 patients (6.8%) 
at site B. At Site C, with a sample of only 206 HIV-positive 
women, 129 (62.6%) had Pap smears. Table I lists the PHC Pap 
smear results. Cytology results are reported as classified by 
the NHLS: normal, atypical squamous cells of undetermined 
significance (ASCUS), atypical squamous cells – cannot exclude 
high-grade SIL (ASC-H), low-grade SIL (LSIL), high-grade SIL 
(HSIL), atypical glandular cells of undetermined significance 
(AGUS), adenocarcinoma in situ, or cancer. Most women were 
found to have normal, ASCUS or LSIL Pap smears. Referrals 
for colposcopy at GSH were indicated for 12 (4.1%) of the 
patients undergoing at least one Pap test, only 5 of whom had 
colposcopy (58.3% lost to follow-up after Pap smear).
GSH colposcopy clinic data – descriptive analysis
The final GSH sample included 2 031 women (Table II); 70.0% 
were between 30 and 49 years of age. Over half of all new 
patients were HIV positive by self-report. No contraception 
was used by 633 (31.2%), while just over one-third were 
using long-acting injectable progestins (LAIP). Condom use 
was reported by 210 (10.3%), with only 175 (17.1%) of HIV-
positive patients reporting regular condom use. HAART was 
utilised by 524 (51.3%) of HIV-positive women at the time 
of their index colposcopy visits (self-reported). Co-morbid 
pulmonary tuberculosis, genital herpes and genital warts were 
significantly more likely to be reported in HIV-positive patients 
(p<0.0001, p=0.0026 and p<0.0001, respectively).
Table II presents referring Pap smear and colposcopy 
findings. An HSIL Pap smear was the reason for referral in 
1 187 (58.4%) women. Consistent with referring Pap smear 
results, most women were considered to have CIN 2 or 3 (high-
grade dysplasia) by the colposcopist. LSIL Pap smears were 
seen in 555 (27.3%) of women referred to GSH; 364 (65.6%) of 
them were HIV positive by self-report, and 335 (60.4%) were 
also found to have low-grade dysplasia on colposcopy. 
LLETZ outcomes
LLETZ was performed in 778 patients for treatment of CIN 
(Table III), of whom 360 (46.3%) were HIV positive and 186 
(51.7%) reported using HAART. The loss to follow-up rate 
after LLETZ (patient did not attend 4-month post-procedure 
visit) was 21.9% for patients seen in 2006 and 2007 (LLETZ 
cases from 2008 were excluded, as patients may have been 
scheduled for follow-up after the close of data collection). 
HIV-positive women were significantly more likely than HIV-
negative women to be lost to follow-up after LLETZ (p=0.0280). 
Descriptive statistics were calculated for the presence of 
residual CIN at LLETZ ecto- and endocervical excision 
margins. Both margins were negative in 349 (44.9%) of LLETZ 
cases, and one or both margins were positive for residual CIN 
in 429 cases (55.1%). HIV-positive women undergoing LLETZ 
were significantly more likely to have one or more margins 
positive for residual CIN (p<0.0001).
Post-LLETZ Pap smear results were available for 494 women 
(Table IV). LSIL or a more severe lesion on Pap smear (defined 
as ‘incomplete treatment’) was seen in 149 women (30.2%) 4 
months after LLETZ. HIV-positive women were significantly 
more likely than HIV-negative women to be incompletely 
treated by LLETZ (p<0.0001). The ‘incomplete treatment’ 
group was also significantly more likely to have both excision 
margins positive for residual CIN (p<0.0001). Use of LAIP 
contraceptives, histological grade and self-reported HAART 
use (in HIV-positive subjects) were not significantly associated 
with LLETZ treatment success. 
Positive predictive value of colposcopy
Positive predictive value (PPV) describes the proportion of 
patients with a positive diagnostic test result subsequently 
found to have true disease on confirmatory testing. We 
examined the subgroup of women classified as having CIN 1 
or more severe lesion on colposcopy and identified the 
proportion in this subgroup who had CIN 1 or more severe 
lesion confirmed by histological sampling (biopsy or LLETZ) to 
calculate PPV. The PPV of colposcopy in predicting a 
histological diagnosis of CIN 1 or more severe lesion was 82.6% 
among women who had diagnostic tissue sampling and for 
whom adequate colposcopy results were available (1 787 of the 
sample of 2 031 women). PPV remained robust when stratified 
by self-reported HIV status. In HIV-positive women with 
colposcopy findings and histological results available (N=897) 
the PPV was 83.0%, and in HIV-negative women (N=537) it 
was 81.1%. 
Discussion
Primary health centre data on recently diagnosed HIV-positive 
women revealed that the proportion of patients undergoing 
at least one Pap smear was low (13.1%). HIV-positive women 
over the age of 30 years were preferentially screened at HIV 
clinics. It is possible (though unlikely) that HIV-positive 
women undergo cervical screening at other primary health care 
sites. PHC site C, which served the fewest patients and offered 
primary care and HIV services in a single setting, provided 
almost two-thirds of newly diagnosed HIV-positive women 
with at least one Pap test. Larger HIV clinic sites – with greater 
patient volumes and more fragmented service provision – were 
less successful in linking cervical cancer prevention to HIV 
care. 
Over 80% of women referred to GSH for colposcopy were 
at least 30 years old. It appears that primary health care 
providers are systematically offering Pap smears in accordance 
with national cervical screening guidelines, and are shifting 
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away from opportunistic screening provided in the context of 
antenatal or family planning care. HIV-positive women were 
over-represented in the colposcopy sample. When combined 
with our data from primary care clinics, this finding suggests 
that while Pap rates among HIV-positive women may be low, 
the proportion of HIV-negative women undergoing Pap smears 
may be even lower. HIV-positive women in Cape Town may 
have more frequent contacts with the health care system. Many 
women referred for colposcopy also utilised contraceptive 
methods requiring regular health care encounters (i.e. LAIP, 
tubal ligation). Cape Town women with regular health system 
interactions of any type may have more lifetime Pap smear 
opportunities.
Colposcopy had a PPV of 82.6%, which was not surprising 
given that PPV is directly proportional to disease prevalence 
(known to be high in our sample). It is important to note that 
PPV was not altered by self-reported HIV status. Colposcopy 
has previously been demonstrated to correlate as well with 
histological diagnosis in HIV-positive women as in uninfected 
controls.9 While colposcopy is useful in estimating lesion 
grade, management decisions may still require histological 
confirmation.
Table II. Groote Schuur Hospital colposcopy clinic sample – patient demographic data, referring cytology and colposcopy 
findings 
                 Entire sample    HIV-positive women     HIV-negative women* 
                 (N=2 031)     (N=1 022)     (N=607)
Characteristic                (N (%))     (N (%))      (N (%))
Age group (yrs)
<30                 380 (18.7)     271 (26.5)     87 (14.3)
30 - 49                 1 422 (70.0)     707 (69.2)     452 (74.5)
>50                 229 (11.3)     44 (4.3)      68 (11.2)
Median gravidity                2.0     2.0      3.0
Median parity                2.0     2.0      2.0
Contraceptive use (type)
None                 633 (31.2)     268 (26.2)     217 (35.7)
LAIP                 720 (35.5)     420 (41.1)     196 (32.3)
Combined oral contraceptive               86 (4.2)     21 (2.1)      40 (6.6)
Intrauterine contraceptive device               6 (0.3)     2 (0.2)      4 (0.7)
Tubal ligation                 234 (11.5)     76 (7.4)      84 (13.8)
Vasectomy                8 (0.4)     0 (0.0)      4 (0.7)
Condoms                210 (10.3)     175 (17.1)     25 (4.1)
Other                 22 (1.1)     3 (0.3)      12 (2.0)
Not recorded                112 (5.5)     57 (5.6)      25 (4.1)
Current tobacco use                380 (18.7)     51 (5.0)      209 (34.4)
Co-morbid genital herpes               12 (0.6)     12 (1.2)      0 (0.0)
Co-morbid pulmonary tuberculosis              134 (6.6)     125 (12.2)     6 (1.0)
Co-morbid genital warts               63 (3.1)     57 (5.6)      4 (0.7)
Referring Pap smear result
Normal                13 (0.6)     0 (0.0)      6 (1.0)
ASCUS                 35 (1.7)     6 (0.6)      10 (1.6)
ASC-H                 125 (6.2)     31 (3.0)      52 (8.6)
LSIL                 555 (27.3)     364 (35.6)     119 (19.6)
HSIL                 1 187 (58.4)     602 (58.9)     364 (60.0)
AGUS                 49 (2.4)     2 (0.2)      26 (4.3)
Adenocarcinoma in situ               11 (0.5)     1 (0.1)      5 (0.8)
Cancer                 54 (2.7)     16 (1.6)      25 (4.1)
Not recorded                2 (0.1)     0 (0.0)      0 (0.0)
Colposcopy finding 
Normal                159 (7.8)     58 (5.7)      53 (8.7)
Squamous metaplasia               120 (5.9)     55 (5.4)      29 (4.8)
CIN 1                 698 (34.4)     428 (41.9)     171 (28.2)
CIN 2, 3                881 (43.4)     426 (41.7)     294 (48.4)
Micro-invasion                49 (2.4)     18 (1.8)      17 (2.8)
Cancer                 47 (2.3)     4 (0.4)      24 (4.0)
Other                 10 (0.5)     3 (0.3)      5 (0.8)
Inadequate                52 (2.6)     23 (2.3)      10 (1.6)
Not recorded                15 (0.7)     7 (0.7)      4 (0.7)
*402 women (19.8% of entire sample) were of unknown HIV status. 
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A substantial proportion of women referred for colposcopy 
(27.3%) had low-grade SIL according to cytology, and most 
of these were HIV positive. Although the relative risk of 
progression of low-grade lesions to high-grade CIN/cancer 
is increased in HIV-positive women, the absolute risk of 
progression remains low.10 In a study of HIV-positive women 
from Cape Town, Denny et al. demonstrated that while 35% 
of women had LSIL on Pap smear at entry, only 4% of them 
progressed to high-grade SIL over a 36-month follow-up 
period.4 However, referrals of low-grade dysplasia to GSH 
probably represent a small fraction of the true number of 
women requiring colposcopy, given the low Pap smear rates 
reported at PHC sites, and the requirement of two low-grade 
Pap smear abnormalities for colposcopy referral. As cervical 
screening increases, the number of cases of low-grade cervical 
disease requiring follow-up is likely to outpace growth in 
colposcopy services.
We found a post-LLETZ patient default rate of over 20%. 
This is concerning, as HIV-positive women were most often 
lost to follow-up. Those HIV-positive women who did follow 
up were significantly more likely to present with Pap smear 
abnormalities after LLETZ. Our suboptimal LLETZ treatment 
outcomes mirror studies in South Africa, Brazil and the 
USA.11-13 HIV-positive women may require more intensive 
surveillance for persistent cervical abnormalities after LLETZ. 
HAART therapy was not associated with improved excision 
outcomes in HIV-positive women in our sample. Studies on 
HAART and CIN excision are mixed; while some suggest that 
HAART promotes regression of CIN/SIL after excision,14 others 
have not shown any clear cervix-specific treatment benefit.15 
However, HAART use was self-reported in our sample, and we 
had no data on duration of therapy.
Limitations and further directions
A retrospective design limited this study’s findings, as research 
questions were restricted to data recorded in clinic folders 
and registers. Data on severity of HIV-related disease (i.e. 
CD4 count, viral load) were unavailable, and the impact of 
these factors on study outcomes could not be assessed. HIV 
status was self-reported in the GSH sample – many women 
who reported ‘negative’ HIV status had last been tested more 
than 12 months before index colposcopy encounters. The large 
proportion of HIV-positive women in our sample may be an 
underestimate.
Our study illustrates the realities of Cape Town’s cervical 
cancer prevention programme for women living with HIV. The 
Table III. Histological diagnosis after LLETZ 
         All LLETZ excisions   HIV-positive women        HIV-negative women*
         (N=778)   (N=360)          (N=252)
Histological diagnosis       (N (%))   (N (%))          (N (%))
Normal/negative        40 (5.1)   13 (3.6)          19 (7.5)
HPV only         8 (1.0)    4 (1.1)          4 (1.6)
CIN 1         83 (10.7)   43 (11.9)          25 (9.9)
CIN 2, 3         623 (80.1)   294 (81.7)          194 (77.0)
Micro-invasion        8 (1.0)    1 (0.3)          3 (1.2)
Adenocarcinoma in situ       2 (0.3)    0 (0.0)          0 (0.0)
Cancer         14 (1.8)   5 (1.4)          7 (2.8)
*166 women of unknown HIV status underwent LLETZ.
Table IV. Post-LLETZ Pap smear results (taken 4 months post-procedure)
               HIV-positive       HIV positive,   HIV positive, 
    All LLETZs           women       on HAART  not on HAART
Post-LLETZ   (N=494)           (N=219)       (N=118)  (N=101)
Pap smear result   (N (%))           (N (%))       (N (%))  (N (%))
Normal    319 (64.6)           105 (47.9)       48 (40.7)  57 (56.4)
ASCUS     26 (5.3)           12 (5.5)       6 (5.1)   6 (5.9)
ASC-H*    3 (0.6)           3 (1.4)       3 (2.5)   0 (0.0)
LSIL*    106 (21.5)           77 (35.2)       51 (43.2)  26 (25.7)
HSIL*    39 (7.9)           22 (10.0)       10 (8.5)  12 (11.9)
AGUS*    1 (0.2)           0 (0.0)       0 (0.0)   0 (0.0)
Adenocarcinoma in situ*  0 (0.0)           0 (0.0)       0 (0.0)   0 (0.0)
Cancer*    0 (0.0)           0 (0.0)       0 (0.0)   0 (0.0)
Total incomplete treatment  149 (30.2)           102 (46.6)       64 (54.2)  38 (37.6)
*Incomplete treatment of CIN by LLETZ. 
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proportion of HIV-positive women undergoing Pap smears at 
HIV care sites is low, and varies highly by clinic site. In spite 
of low Pap test rates, many HIV-positive women are being 
referred for colposcopy. Poor follow-up after excision coupled 
with suboptimal CIN treatment outcomes in HIV-positive 
women means that cervical surveillance efforts must be scaled 
up for these patients. New recommendations for follow-up in 
these women will impact on the allocation of health resources 
for cervical cancer prevention. Cervical cancer prevention must 
be linked to basic HIV care for health outcomes to improve.
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